Zimmer Biomet Holdings, Inc (ZBH) FinancialsZBHFinancialZimmer Biomet Holdings, Inc

Zimmer Biomet Holdings, Inc. (ZBH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Knees, accounting for 38.1% of total sales, equivalent to $828.90M. Other significant revenue streams include S E T and Hips. Understanding this composition is critical for investors evaluating how ZBH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Zimmer Biomet Holdings, Inc. maintains a gross margin of 63.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.00%, while the net margin is 9.17%. These profitability ratios, combined with a Return on Equity (ROE) of 6.42%, provide a clear picture of how effectively ZBH converts its operational activities into shareholder value.

In the context of the broader market, ZBH competes directly with industry leaders such as GH and STE. With a market capitalization of $19.20B, it holds a significant position in the sector. When comparing efficiency, ZBH's gross margin of 63.30% stands against GH's 65.39% and STE's 45.84%. Such benchmarking helps identify whether Zimmer Biomet Holdings, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown consistent revenue growth, with Q2 2026 revenue at $2.18 billion, surpassing expectations and reflecting a strong demand for its products. The gross margin is healthy at around 63.30%, indicating efficient cost management.